Cargando…

Use of activated clotting time to monitor anticoagulation in patients receiving unfractionated heparin on renal replacement therapy

Detalles Bibliográficos
Autores principales:	Bidwai, A, Sundaram, R
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3061752/ http://dx.doi.org/10.1186/cc9542

Ejemplares similares

Comparison between nafamostat mesilate and unfractionated heparin as anticoagulant during continuous renal replacement therapy
por: Makino, S, et al.
Publicado: (2015)

Monitoring Anticoagulation with Unfractionated Heparin on Renal Replacement Therapy. Which is the Best aPTT Sampling Site?
por: Anton, Florin Ioan, et al.
Publicado: (2020)

Anticoagulation during continuous renal replacement therapy with lepirudin in patients with heparin-induced thrombocytopenia
por: Schroeder, T, et al.
Publicado: (2005)

Time in the Therapeutic Range for Assessing Anticoagulation Quality in Patients Receiving Continuous Unfractionated Heparin
por: Ting, Clara, et al.
Publicado: (2018)

Differences in activated clotting time and total unfractionated heparin dose during pulmonary vein isolation in patients on different anticoagulation therapy
por: Zeljkovic, Ivan, et al.
Publicado: (2021)

Impact of nebulized unfractionated heparin and N-acetylcysteine in management of smoke inhalation injury
por: Elamin, E, et al.
Publicado: (2009)

Unfractionated and low molecular weight heparin
por: Lima, Marcelo, et al.
Publicado: (2014)

Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study
por: Kameda, Shinya, et al.
Publicado: (2023)

Extracorporeal renal replacement therapy in patients with heparin-induced thrombocytopenia
por: Bekers-Anchipolovskis, M, et al.
Publicado: (2009)

Correction: Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study
por: Kameda, Shinya, et al.
Publicado: (2023)

Validation of high concentrated thrombin time assay for unfractionated heparin monitoring
por: Apipongrat, Dollapak, et al.
Publicado: (2022)

Recurrent early filter clotting in regional citrate anticoagulated continuous venovenous hemodialysis due to undetected antibodies to heparin-platelet factor 4 complexes
por: Slowinski, T, et al.
Publicado: (2010)

Impact of COVID-19 on monitoring of therapeutic unfractionated heparin
por: Adie, Sarah K., et al.
Publicado: (2020)

Heparin algorithm for anticoagulation during continuous renal replacement therapy
por: Ostermann, Marlies, et al.
Publicado: (2010)

Establishing the heparin therapeutic range using aPTT and anti-Xa measurements for monitoring unfractionated heparin therapy
por: Byun, Jung-Hyun, et al.
Publicado: (2016)

Laboratory Assessment of Unfractionated Heparin (UFH) with Activated Clotting Time (ACT) and Anti-Xa Activity during Peripheral Arterial Angiographic Procedure
por: Helin, Tuukka, et al.
Publicado: (2023)

Association between type of anticoagulation and blood transfusion requirements during renal replacement therapy in the ICU
por: Iyer, A, et al.
Publicado: (2011)

Is the ecarin clotting time (ECT) a valid monitoring parameter for r-hirudin-based anticoagulation in continuous renal replacement therapy?
por: v Heymann, C, et al.
Publicado: (2000)

Clinical review: Anticoagulation for continuous renal replacement therapy - heparin or citrate?
por: Oudemans-van Straaten, Heleen M, et al.
Publicado: (2011)

Heparin vs recombinant hirudin for anticoagulation in continuous renal replacement therapy
por: Vargas Hein, O, et al.
Publicado: (2000)

Revised algorithm for heparin anticoagulation during continuous renal replacement therapy
por: Dickie, Helen, et al.
Publicado: (2015)

Unfractionated heparin and mechanical thromboprophylaxis in hip arthroplasty
por: Garcia, Flávio Luís, et al.
Publicado: (2015)

Safety of drotrecogin alfa (activated) treatment in patients with severe sepsis on renal replacement therapy without additional anticoagulation
por: Mirea, L, et al.
Publicado: (2011)

Evaluation of functional differences between two anticoagulation methods used in continuous renal replacement therapy in critical patients
por: Goulão, V, et al.
Publicado: (2014)

An Antithrombin-Heparin Complex Increases the Anticoagulant Activity of Fibrin Clots
por: Smith, Lesley J., et al.
Publicado: (2008)

Long-term renal and survival outcomes in acute kidney injury patients receiving renal replacement therapy in intensive care
por: Elsayed, I, et al.
Publicado: (2015)

Combined use of pumpless extracorporeal lung assist system and continuous renal replacement therapy with citrate anticoagulation in polytrauma patients
por: Atalan, HK, et al.
Publicado: (2013)

Predicting Therapeutic Response to Unfractionated Heparin Therapy: Machine Learning Approach
por: Abdel-Hafez, Ahmad, et al.
Publicado: (2022)

Bivalirudin or heparin: which anticoagulation strategy for critically ill cardiac surgery patients?
por: Pappalardo, F, et al.
Publicado: (2014)

Blood transfusion requirements and filter longevity with regional citrate anticoagulation compared with heparin
por: Burford, E, et al.
Publicado: (2015)

Citrate versus heparin anticoagulation in continuous renal replacement therapy in small children
por: Raymakers-Janssen, Paulien A. M. A., et al.
Publicado: (2017)

Enoxaparin versus Unfractionated Heparin for the Perioperative Anticoagulant Therapy in Patients with Mechanical Prosthetic Heart Valve Undergoing Non-Cardiac Surgery
por: Iliuta, Luminita, et al.
Publicado: (2022)

Alternatives to standard unfractionated heparin for pediatric hemodialysis treatments
por: Davenport, Andrew
Publicado: (2012)

Quantitative Analysis of Impurities in Unfractionated Heparin of Bovine Origin
por: Workman, Wesley E., et al.
Publicado: (2020)

Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa
por: Lewis, Joseph, et al.
Publicado: (2022)

Resistance to unfractionated heparin in the ICU: evaluation and management options
por: Levy, Jerrold H., et al.
Publicado: (2023)

Monitoring of Unfractionated Heparin in Severe COVID-19: An Observational Study of Patients on CRRT and ECMO
por: Streng, Alexander S., et al.
Publicado: (2020)

Daily fluid balance predicts hospital mortality in critically ill patients receiving continuous renal replacement therapy
por: Kashiouris, M, et al.
Publicado: (2013)

Evaluation of anti-Xa levels in patients with venous thromboembolism within the first 48 h of anticoagulation with unfractionated heparin
por: Nguyen, Lily, et al.
Publicado: (2023)

Comments on ‘Comparison of anticoagulation strategies for veno-venous ECMO support in acute respiratory failure’: the bitter truth about unfractionated heparin monitoring assays
por: Moussa, Mouhamed Djahoum, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lvd1r88c5oe2qgvi73ndj4icm9